--- title: "Weekly Recap | AIM ImmunoTech -5.31%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/300846321.md" description: "AIM ImmunoTech (AIM.US) fell 5.31% this week to close at $0.18, underperforming the S&P 500, which slipped 0.27%, by roughly 5.04 percentage points. It was a choppy week. The stock opened Monday (Sep 28) at $0.188 and closed at $0.1844, then sold off on Tuesday (Sep 29) to a weekly low of $0.1659 before ending at $0.1735. It recovered through Wednesday and Thursday, reaching $0.1877 on Thursday, and on Friday (Oct 2) it touched a weekly high of $0.1934 before fading to close at $0.18." datetime: "2026-10-03T06:16:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300846321.md) - [en](https://longbridge.com/en/news/300846321.md) - [zh-HK](https://longbridge.com/zh-HK/news/300846321.md) generator: "portal-rs" --- # Weekly Recap | AIM ImmunoTech -5.31%, consensus target above spot ## The Week AIM ImmunoTech (AIM.US) fell 5.31% this week to close at $0.18, underperforming the S&P 500, which slipped 0.27%, by roughly 5.04 percentage points. It was a choppy week. The stock opened Monday (Sep 28) at $0.188 and closed at $0.1844, then sold off on Tuesday (Sep 29) to a weekly low of $0.1659 before ending at $0.1735. It recovered through Wednesday and Thursday, reaching $0.1877 on Thursday, and on Friday (Oct 2) it touched a weekly high of $0.1934 before fading to close at $0.18. Weekly amplitude was 14.63%, and average daily volume of about 1.43 million shares ran 17.7% above the median. ## Key Events The week’s company-specific story centred on Ampligen’s role in pancreatic cancer treatment. On Wednesday, Sep 30, AIM ImmunoTech published a new CEO Corner video discussing Ampligen’s potential to complement emerging pancreatic cancer therapies. The same day, the company said it expects to report topline data from the Phase 2 DURIPANC trial of Ampligen plus durvalumab in metastatic pancreatic cancer in Q1 2027. On Thursday, Oct 1, it reiterated that timeline and the trial’s progress. Regulatory filings during the week were routine: a DEF 14A proxy statement and an ARS annual report were submitted on Oct 1, with no new business updates. ## Analyst Ratings Two brokers cover AIM ImmunoTech: one rates it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus recommendation is buy, and the consensus target price of $4.25 implies a 2261.11% premium to the $0.18 closing price. Targets span a wide range from $1.50 to $7.00, pointing to considerable disagreement about the company’s longer-term value. Within the biotechnology industry, its rating rank sits at 391 out of 507 companies. ## The Week Ahead On the macro side, the US releases S&P Global services PMI final and ISM non-manufacturing PMI on Monday, Oct 5 — the ISM reading has a prior of 55.4 and a consensus of 55. On Tuesday, Oct 6, the international trade balance is due, with a prior of -88.6 and a consensus of -102. Wednesday, Oct 7 brings weekly EIA crude inventories and Cushing crude inventories. These may shift overall risk appetite, but for a mid-to-tail biotech name like AIM.US, the more relevant watch item is whether management provides any further update on DURIPANC or additional colour on Ampligen’s clinical and regulatory path. ## In Short AIM ImmunoTech’s 5.31% weekly drop came with an underperformance against the broader market, yet the underlying narrative did not deteriorate in step. Ampligen’s progress in combination therapy for pancreatic cancer was emphasised repeatedly, brokers rate the stock buy with a target far above spot, and the PB ratio of 0.83 still puts market value below book value per share. At the same time, the latest trading day’s flows show large-lot money as a net seller while small and medium orders were net buyers, a split that leaves the near-term direction unsettled. The tension sits between a positive clinical story and constructive broker views on one side, and weak price action plus uneven flows on the other — so the key monitor remains any DURIPANC update ahead of topline data, and whether large-lot flows turn back toward net buying. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [AIM.US](https://longbridge.com/en/quote/AIM.US.md) ## Related News & Research - [AIM ImmunoTech CEO Thomas K Equels acquires common shares worth $4,992](https://longbridge.com/en/news/299448153.md) - [AIM ImmunoTech CEO Thomas K. Equels acquires $4,862 common shares](https://longbridge.com/en/news/299189774.md) - [Nokia Q3 profit rises 95% to EUR 156 million](https://longbridge.com/en/news/302649426.md) - [Bloom Energy’s October Stock Slump Deepens: Options Signal Post-Earnings Bounce to $230](https://longbridge.com/en/news/302763129.md) - [Micron introduces quarterly employee bonus tied to profits](https://longbridge.com/en/news/302675659.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**